Cargando…

3542 Torsade de pointes/QT prolongation risks with antibiotics: A contemporary analysis of the FDA Adverse Event Reporting System

OBJECTIVES/SPECIFIC AIMS: Macrolides, linezolid, imipenem-cilastatin, fluoroquinolones, penicillin combinations, and ceftriaxone are known to be associated with Torsade de pointes/QT prolongation (TdP/QTP). Other antibiotics may also lead to TdP/QTP, but no study has systemically compared TdP/QTP ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Chengwen, Gaspar, Daryl Kevin S., Frei, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2019
Materias:	Clinical Epidemiology/Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798461/ http://dx.doi.org/10.1017/cts.2019.135

Ejemplares similares

Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)

DOTHIEPIN, QT PROLONGATION AND TORSADES DE POINTES
por: Andrade, Chittaranjan, et al.
Publicado: (1999)

QT prolongation and torsades de pointes with psychotropic agents
por: Desai, Nagaraj, et al.
Publicado: (2015)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects
por: Darpö, Börje, et al.
Publicado: (2013)

QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine
por: Malone, Katie, et al.
Publicado: (2020)

Chlorine. (CL.—35.42.)
por: Watt, G.
Publicado: (1855)

Recurrent takotsubo with prolonged QT and torsade de pointes and left ventricular thrombus
por: Ahmed, Alaa Eldin K., et al.
Publicado: (2017)

Chloroquine/erythromycin: QT interval prolongation and Torsade de Pointes: case report
Publicado: (2020)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

QT Interval Prolongation as a Biomarker for Torsades de Pointes and Sudden Death in Drug Development
por: Sides, Gregory D.
Publicado: (2002)

Torsades de pointes induced by concomitant use of chlorpheniramine and propranolol: An unusual presentation with no QT prolongation
por: Ösken, Altuğ, et al.
Publicado: (2016)

Torsades de Pointes associated with QT prolongation after catheter ablation of paroxysmal atrial fibrillation
por: Park, Yae Min, et al.
Publicado: (2017)

The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department
por: Cole, Jon B., et al.
Publicado: (2020)

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin
por: Chorin, Ehud, et al.
Publicado: (2020)

Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine
por: Sarayani, Amir, et al.
Publicado: (2021)

Mechanisms of fever-induced QT prolongation and torsades de pointes in patients with KCNH2 mutation
por: Usuda, Keisuke, et al.
Publicado: (2023)

QT Dispersion and Drug-Induced Torsade de Pointes
por: Friedman, Ari, et al.
Publicado: (2021)

QT Prolongation Complicated with Torsades de Pointes in Prosthetic Mitral Valve Endocarditis: A Case Report
por: Tounsi, A., et al.
Publicado: (2012)

QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H(1) receptor antagonists
por: Acosta-Materán, Carlos, et al.
Publicado: (2016)

Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re‐evaluation of an established drug
por: Schlit, Anne‐Françoise, et al.
Publicado: (2017)

A Case of Hypoglycemiainduced QT Prolongation Leading to Torsade de Pointes and a Review of Pathophysiological Mechanisms
por: Hannoodi, Faris, et al.
Publicado: (2017)

Ceftriaxone/hydroxychloroquine/tocilizumab: QT prolongation, torsade-de-pointes and off label use: case report
Publicado: (2020)

Comment on “The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department”
por: DiSalvo, Philip C., et al.
Publicado: (2021)

His Bundle Pacing in Amiodarone-Induced Complete Heart Block, QT Prolongation, and Torsade de Pointes
por: Tan, Vern Hsen, et al.
Publicado: (2020)

Torsade de Pointes Due to QT Prolongation after Pulmonary Vein Isolation for Persistent Atrial Fibrillation
por: Chikata, Akio, et al.
Publicado: (2021)

Diphenhydramine-Induced Torsade De Pointes With Pharmacological Cardioversion in a Patient With Methadone-Induced QT Prolongation
por: Hoffman, Jamie P, et al.
Publicado: (2022)

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects
por: Täubel, Jörg, et al.
Publicado: (2016)

Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes
por: El-Sherif, Nabil, et al.
Publicado: (2019)

QT interval prolongation and torsade de pointes induced by left ventricular pacing rescued by His bundle pacing
por: Lador, Adi, et al.
Publicado: (2020)

4448 Mental Stress Induced Myocardial Ischemia as a Marker for Adverse Cardiovascular Events After MI
por: Almuwaqqat, Zakaria, et al.
Publicado: (2020)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Recurrent Torsades with Refractory QT Prolongation in a 54-Year-Old Man
por: Guess, Joel, et al.
Publicado: (2018)

Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study
por: Mendzelevski, Boaz, et al.
Publicado: (2012)

Long QT Syndrome and Torsade de Pointes Associated with Takotsubo Cardiomyopathy
por: Ahn, Ji Hun, et al.
Publicado: (2011)

Long QT syndrome and torsade de pointes after anthracycline chemotherapy
por: Colombo, N, et al.
Publicado: (2009)

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
por: Darpo, Borje, et al.
Publicado: (2015)

Hydroxychloroquine-associated QT interval prolongation
Publicado: (2020)

2296. Hypoglycemia Risk with Antibiotics: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
por: Kennedy, Kaitlin E, et al.
Publicado: (2019)

Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)

2172. Assessment of Cefepime Neurotoxicity in the FDA Adverse Reporting System
por: Groff, Lindsey, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fr8vc70je4dh1qkrdtjujmlesg